A dose-ranging study of tiotropium delivered via Respimat® Soft MistTM Inhaler or HandiHaler® in COPD patients by Caillaud, Denis et al.
© 2007 Caillaud et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article 
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of COPD 2007:2(4) 559–565 559
ORIGINAL RESEARCH
A dose-ranging study of tiotropium delivered 
via Respimat® Soft MistTM Inhaler or HandiHaler® 
in COPD patients
Denis Caillaud1
Charles Le Merre2
Yan Martinat3
Bernard Aguilaniu4
Demetri Pavia5
1CHU Clermont-Ferrand, Pulmonary 
Department, Hôpital G Montpied, 
Clermont-Ferrand, France; 2Service 
de Pneumologie-Médecine A, Nîmes, 
France; 3Centre Médical PAROT, Lyon, 
France; 4HYLAB Physiologie Clinique 
et Exercise, Grenoble, France; 
5Clinical Research Department, 
Medical Division, Boehringer 
Ingelheim Ltd, Bracknell, Berkshire, UK
Correspondence: Demetri Pavia
Clinical Research Department, Medical 
Division, Boehringer Ingelheim Ltd, 
Ellesﬁ  eld Avenue, Bracknell, Berkshire, 
RG12 8YS, UK
Tel +44 1344 741264
Email paviad@bra.boehringer-ingelheim.com
Abstract: This was a multicenter, randomized, double-blind within device, parallel-group, 
dose-ranging study. COPD patients (n = 202; 86% male; mean age: 61 years) were randomized 
to receive tiotropium 1.25 μg, 2.5 μg, 5 μg, 10 μg, or 20 μg Respimat® SMI (a novel, propellant-
free device); tiotropium 18 μg HandiHaler®; placebo Respimat®; or placebo HandiHaler® for 3 
weeks. The primary endpoint was trough FEV1 on Day 21. Other assessments included FVC, 
PEFR, rescue medication use, safety, and pharmacokinetics. In general, all active treatments 
improved the primary and secondary endpoints on Day 21 (steady state) compared with 
placebo. Tiotropium 5 μg Respimat®, 20 μg Respimat®, and tiotropium 18 μg HandiHaler® 
were statistically signiﬁ  cantly higher than placebo for the primary endpoint (mean change in 
trough FEV1 was 150 mL (both Respimat® doses) versus 20 mL (placebo Respimat®); p   0.05; 
and 230 mL (HandiHaler®) versus −90 mL (placebo HandiHaler®); p   0.001). The urinary 
excretion (up to 2 hours post-dose) of tiotropium 5–10 μg Respimat® was comparable with 
tiotropium 18 μg HandiHaler®; the overall incidence of adverse events was comparable across 
treatment groups. Tiotropium 5 and 10 μg Respimat® improve lung function in COPD patients 
and appear to be comparable with tiotropium 18 μg HandiHaler®.
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Introduction
Tiotropium is well established as a ﬁ  rst-line maintenance treatment in patients with 
chronic obstructive pulmonary disease (COPD) (ATS 1995; GOLD 2005; Saberi and 
O’Donnell 2005). Once-daily administration of this antimuscarinic agent provides 
24-hour bronchodilation via prolonged blockade of muscarinic M3-receptors. At 
present, tiotropium is delivered via HandiHaler® (Boehringer Ingelheim, Ingelheim 
am Rhein, Germany) a dry-powder, breath-actuated inhaler, and this drug/delivery 
combination has many supporting clinical data (Niewoehner et al 2000; Casaburi et al 
2002; Vincken et al 2002; O’Donnell et al 2004; Maltais et al 2005). Previous dose-
ranging studies have shown that tiotropium 18 μg is the optimal dose for use with 
HandiHaler® and this is the marketed dose with this device (Maesen et al 1995).
More recently, an innovative delivery device, the Respimat® Soft MistTM 
Inhaler (SMI), has been developed (Boehringer Ingelheim, Ingelheim am Rhein, 
Germany). This multi-dose, propellant-free device, is powered by a compressed 
spring inside the inhaler (Dalby et al 2004; Zierenberg 1999), and the dose is loaded 
when the lower half of the device is turned through 180 degrees. This draws drug 
into the micropump, which is then released when the patient presses the dose-release 
button. The aerosol from the Respimat® SMI has a much lower velocity and longer 
duration than that observed with pressurized metered-dose inhalers (pMDIs), and 
the ﬁ  ne particle fraction (<5.8 μm) in Respimat® SMI accounts for 66% of aqueous International Journal of COPD 2007:2(4) 560
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drug solution (Hochrainer et al 2005; Zierenberg 1999). As 
a result, Respimat® SMI improves lung drug deposition, 
reduces oropharyngeal deposition, and may require a lower 
dose of drug than that normally used with either dry powder 
inhalers (DPIs) or pMDIs (Newman et al 1998; Newman 
1999; Pitcairn et al 2005).
Against this background, the aim of this dose-ranging 
study was to establish the doses of tiotropium that are most 
efﬁ  cacious with Respimat® SMI in patients with COPD. The 
maximum dose used in this study was tiotropium 20 μg. It 
was hypothesized that a lower dose would be needed than 
that used with HandiHaler® due to higher lung deposition 
with the Respimat® SMI device.
Materials and methods
Study design
This was a 3-week, multicenter, randomized, double-blind 
within device, parallel-group, active- and placebo-controlled, 
dose-ranging study (Study #205.127), which was performed 
in 15 centers across France. The study was designed to 
determine the dose(s) of tiotropium that were efﬁ  cacious 
with Respimat® SMI, and to compare these doses with the 
marketed tiotropium 18 μg HandiHaler® in patients with 
COPD. Five different doses of tiotropium inhalation solution 
(1.25 μg, 2.5 μg, 5 μg, 10 μg, and 20 μg) were chosen for 
use with Respimat® SMI. Tiotropium 18 μg HandiHaler® was 
used as the active control. Placebo HandiHaler® and placebo 
solution Respimat® SMI were used as placebo controls with 
each respective device. The study was conducted from March 
1998 to April 1999. It was performed in accordance with the 
Declaration of Helsinki, to the requirements of Good Clinical 
Practice principles and local regulations, and was sponsored 
by Boehringer Ingelheim.
Inclusion and exclusion criteria
Males or females aged  40 years with a diagnosis of COPD 
(30%  FEV1  65% of predicted normal value [Quanjer et al 
1993] and FEV1/FVC  70%), and a smoking history  10 
pack-years were eligible. Patients with a history of asthma, 
rhinitis, atopy, a clinically signiﬁ  cant disease, or a lower 
respiratory tract infection or exacerbation within the last 6 
weeks were excluded. Pregnant women, nursing women, 
and women of childbearing potential not using contraception 
were also excluded. All patients provided written, informed 
consent to participate.
Cromolyn, nedocromil sodium, anticholinergics, 
antihistamines, hydroxyzine, astemizole, long-acting beta-
agonists, other investigational drugs and regular use of daytime 
oxygen therapy were not allowed during the study. Any rescue 
medication considered appropriate by the physician, inhaled 
corticosteroids, and oral corticosteroids if stabilized within 
the 6 weeks prior to study entry (ie,  10 mg prednisone per 
day or equivalent) were allowed. Short-acting beta-agonists 
and oral theophylline were permitted if withdrawn prior to 
clinic visits.
Medication restrictions
Prior to the screening visit (Visit 1), long-acting inhaled 
beta-agonists were not permitted for 48 hours, short-acting 
inhaled anticholinergics were not permitted for 8 hours, and 
long-acting anticholinergics were not permitted for 12 hours 
prior to Visit 1. Short-acting oral beta-agonists were not 
permitted for 18 hours, long-acting oral beta-agonists were 
not permitted for 36 hours, oral anticholinergics (7 days), 
oral antihistamines (48 hours), oral hydroxyzine (96 hours), 
and astemizole (3 months). Tiotropium had never previously 
been administered to patients using Respimat® SMI.
Some medications were allowed throughout the study 
period, but had to be withdrawn prior to clinic visits; these 
agents were as follows (the withdrawal time period is 
indicated in brackets): short-acting inhaled beta-agonists 
(8 hours); short-acting oral theophylline (24 hours); and oral 
slow-release theophylline (48 hours). No washout period was 
required for inhaled corticosteroids; they could be continued 
throughout the study provided the dosage was constant during 
the 6 weeks prior to Visit 1.
Methods
Following screening (Visit 1), eligible patients were random-
ized to receive tiotropium 1.25 μg, 2.5 μg, 5 μg, 10 μg, or 20 μg 
delivered via the Respimat® SMI, tiotropium 18 μg delivered 
via the HandiHaler®, placebo Respimat® SMI, or placebo 
HandiHaler® for 3 weeks. Study drug was administered 
once daily (two puffs via Respimat® SMI or one capsule via 
HandiHaler®) in the morning between 8:00 and 10:00 hours. 
The study was double-blind within device, ie, there was no 
blinding between Respimat® SMI and HandiHaler®.
The primary endpoint was the change from baseline 
(Day 0; Visit 2) in morning pre-dose (ie, trough) FEV1 on Day 
21 (Visit 5), ie, at steady-state. Trough FEV1 was calculated 
using the largest of three FEV1 readings measured during 
the last 2 hours of the 24-hour dosing interval. Secondary 
endpoints included FVC and rescue medication use. Daily peak 
expiratory ﬂ  ow rate (PEFR) measurements were recorded in 
diary cards. The patient was also asked if he/she was awakened 
during the night by coughing or shortness of breath.International Journal of COPD 2007:2(4) 561
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All clinic spirometry measures were performed in 
accordance with ATS criteria (ATS 1995). All pulmo-
nary function tests were conducted while the patient was 
in a seated position. At each time point, the spirometric 
manoeuvres were conducted in triplicate and the largest 
FEV1 and largest FVC were recorded after examining all of 
the acceptable curves. The timing of the baseline pulmonary 
function testing always started at the same time of day (07:00 
hours ± 1 hour). A time window of 1 hour was permitted 
between the start (baseline pulmonary testing) on the ﬁ  rst 
day (Day 0, Visit 2) and the start on the three other test days 
(Day 7 [Visit 3], Day 14 [Visit 4], and Day 21 [Visit 5]). The 
timing of subsequent hourly lung function testing during 
Visits 2, 3, 4, and 5 varied; a time window of 1 hour was 
permitted during these subsequent measures. FEV1 and FVC 
were measured at least 2 hours pre-dose and up to 4 hours 
(240 minutes) post-dose.
Adverse events were recorded throughout the trial. 
Changes in vital signs (electrocardiogram [ECG], heart rate, 
pulse rate, blood pressure) were recorded on test days (Days 
0, 7, 14, and 21), and physical examinations and routine 
laboratory tests were recorded before and after the trial.
Pharmacokinetics
Urine samples were collected in two fractions lasting from −2 
to 0 hours (± 5 minutes) pre-dose and from 0 to 2 hours 
(± 5 minutes) post-drug inhalation on Days 7, 14, and 21 
(± 2 days). Diuresis was aided by the intake of 100 mL of 
water during both collection periods. Tiotropium concentra-
tions were measured using a validated high-performance 
liquid chromatography coupled with tandem mass spec-
trometry (HPLC-MS/MS) assay. The assay had a limit 
of quantiﬁ  cation of 10 pg/mL. The amount of tiotropium 
excreted unchanged in the urine (Ae) was determined pre- 
and post-dose; excretion data at steady state were evaluated 
between Days 7, 14, and 21 (± 2).
Analysis
The primary analysis was designed to test whether each 
dose of tiotropium Respimat® SMI was more effective than 
placebo. The primary endpoint and secondary clinic spirometry 
endpoints were evaluated by an analysis of covariance 
(ANCOVA) with baseline data as a covariate and treatment 
effect as a factor. Descriptive statistics were used for other 
secondary efﬁ  cacy variables, safety, and pharmacokinetic 
data. All treated patients were included in the safety analysis. 
The intent-to-treat (ITT) population consisted of all patients 
who had been randomized to treatment, received at least 
one dose of drug, and had at least one valid baseline and one 
post-treatment evaluation. Using a standard deviation for 
average FEV1 post-drug administration of  0.17 L, a total of 
192 patients (24 patients per treatment group) was planned 
to detect a 150 mL difference in mean FEV1 response 
between tiotropium Respimat® SMI and placebo at 5% level 
of signiﬁ  cance with at least 80% power using a two-tailed 
t-test.
Results
Patient characteristics and disposition
A total of 294 patients were screened, and 202 eligible patients 
were randomized to treatment. Patient characteristics are 
shown in Table 1. The treatment groups were well matched 
in terms of age, COPD duration, lung function, and tobacco 
consumption (comparative data not shown). The majority 
were male (85.6%), the mean age was 60 years, the mean 
baseline FEV1 (% predicted) was 43.6%, the mean COPD 
duration was 10.5 years, and the mean tobacco consumption 
was 44.7 pack-years. Concomitant medication use was 
similar between treatment groups; 79.7% used beta-agonists, 
62% used inhaled steroids, and 27.2% used theophylline. 
A total of 11 patients (5.4%) discontinued prematurely 
(3 for worsening of disease under study; 2 for worsening of 
pre-existing disease; 3 for other adverse events (AEs); 1 was 
not compliant; and 2 withdrew their consent).
Efﬁ  cacy endpoints
The primary endpoint, trough FEV1, was statistically 
signiﬁ  cantly improved following treatment with tiotropium 
5 μg Respimat® SMI, 20 μg Respimat® SMI, and tiotropium 
18 μg HandiHaler® compared with placebo (p   0.05) (Table 2). 
Tiotropium 10 μg Respimat® SMI showed a similar numerical 
advantage over placebo as that observed with the 5 μg and 20 
μg Respimat® SMI doses; however, the difference approached, 
but did not reach, statistical signiﬁ  cance (p = 0.06).
Table 1  Baseline characteristics* of randomized patients 
(n = 202)
Age (years)  60.2 (9.6)
Male, n(%)  173 (85.6)
Ex-smoker, n(%)  112 (55.4)
Smoking history (pack-years)  44.7 (17.9)
Duration of COPD (years)  10.5 (7.9)
FEV1 (L)  1.31 (0.40)
FEV1 (% predicted)  43.6 (10.5)
FVC (L)  2.64 (0.66)
*Mean (SD) unless otherwise stated.
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital 
capacity.International Journal of COPD 2007:2(4) 562
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Mean FEV1 was sustained above placebo for all active 
treatments throughout the study; the improvements following 
treatment on Day 21 (steady state) are shown in Figure 1. At 
other time points, only the tiotropium 5 μg Respimat® SMI 
and tiotropium 18 μg HandiHaler® doses reached statisti-
cal signiﬁ  cance on both Days 7 and 14 (largest: p   0.05) 
(Table 2). FVC also improved after treatment with tiotropium 
Respimat® SMI and HandiHaler® compared with placebo. On 
Day 21, the greatest improvements in FVC were observed 
with the tiotropium 5 μg and 20 μg Respimat® SMI dose 
and with tiotropium 18 μg HandiHaler® (Table 3). All active 
treatments improved morning and evening PEFR on Day 21 
compared with placebo (largest: p   0.05) (Table 3). Rescue 
medication use declined in all active treatment groups, and 
with the exception of tiotropium 2.5 μg Respimat® SMI, 
the mean decrease for each treatment group was statisti-
cally different from placebo (p   0.05). A trend in favor of 
active treatment over placebo was observed for nocturnal 
awakenings (data not shown).
Pharmacokinetics
The urinary excretion of tiotropium Respimat® SMI at steady 
state, measured from −2 hours to 0 hours pre-dose and from 
0 to 2 hours post-dose on Day 21, was dose-dependent as 
shown in Figure 2. For both the pre- and post-dose measures, 
the urinary excretion of tiotropium 5–10 μg Respimat® SMI 
was comparable with that of tiotropium 18 μg HandiHaler®.
Safety
During the 3-week treatment period, 27.7% (56/202) of 
randomized patients reported AEs. The overall incidence 
of AEs was comparable across all active treatment groups 
and placebo. The most frequently reported AEs are shown 
in Table 4. Dry mouth was more common in the active 
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Figure 1  The adjusted* mean change in FEV1 following tiotropium administration on Day 21 (ie, steady state). 
*Change from study baseline. 
Abbreviation: SMI, Soft MistTM Inhaler.
Table 2  Mean‡ (SEM) primary and secondary trough FEV1 measurements 
 Respimat® SMI  HandiHaler®
 Dose,  μg 1.25  2.5  5  10  20  PBO  18  PBO
  n,  ITT 25  28 25 26  26 24 25 23
  Primary endpoint
Day 21   Trough   0.10   0.05   0.15*   0.13   0.15*   0.02   0.23†   −0.09 
(steady state)  FEV1, L   (0.04)  (0.03)  (0.04)  (0.03)  (0.04)  (0.04)  (0.05)  (0.05)
  Secondary FEV1 endpoints
Day 7  Trough   0.13*   0.10   0.16*   0.08   0.12   0.03   0.22†   −0.08 
 FEV1, L   (0.03)  (0.03)  (0.03)  (0.03)  (0.03)  (0.03)  (0.05)  (0.05)
Day 14  Trough   0.13   0.08   0.17*   0.02   0.17*   0.02   0.22†   −0.04 
 FEV1,  L  (0.04)  (0.04) (0.04) (0.04)  (0.04) (0.04) (0.05) (0.05)
*p < 0.05; †p ≤ 0.001; ‡change from study baseline. 
Abbreviations: FEV1, forced expiratory volume in 1 second; ITT, intent-to-treat; PBO, placebo; SEM, standard error of mean; SMI, Soft MistTM Inhaler.International Journal of COPD 2007:2(4) 563
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treatment groups at doses higher than 5 μg. Eight patients 
withdrew from the study due to an AE: AV block (one patient 
on tiotropium 2.5 μg Respimat® SMI); COPD exacerbations 
(one patient from each of the tiotropium 2.5 μg Respimat® 
SMI, tiotropium 10 μg Respimat® SMI, placebo Respimat® 
SMI, and placebo HandiHaler® groups); dyspnea (one patient 
on tiotropium 18 μg HandiHaler®); pneumonia (one patient 
on tiotropium 1.25 μg Respimat® SMI); and hematuria (one 
patient on tiotropium 2.5 μg Respimat® SMI). Six patients 
had serious adverse events (SAEs) (only one was considered 
to be study related: hematuria [tiotropium 2.5 μg Respimat® 
SMI]). There were no patient deaths during the trial. There 
were no clinically relevant changes in laboratory values 
(hematology, biochemistry), vital signs, or ECG.
Figure 2 Urinary excretion of tiotropium (a) −2 to 0 hours pre-dose and (b) 0 to 2 hours post-dose on Day 21 (ie, steady state). 
Abbreviations: Ae, amount of drug excreted unchanged in urine; SMI, Soft MistTM Inhaler.
Table 3 Mean‡ (SEM) secondary measurements during steady state
 Respimat® SMI  HandiHaler®
 Dose,  μg  1.25  2.5  5  10 20 PBO  18 PBO
  n,  ITT  25 28 25 26 26 24 25 23
Day 21  FVC, L  0.20   0.10   0.27   0.20   0.25   0.11   0.32†   −0.09 
    (0.07) (0.07) (0.07) (0.07) (0.07) (0.07) (0.08) (0.08)
Week 3  Morning   26.1   35.6*   34.7   51.2†   28.5   9.3   39.8†   −5.7 
  PEFR,  L/min  (9.4) (8.7) (9.0) (8.6) (9.0) (9.7) (9.0) (9.2)
Week 3  Evening   39.6*   48.5*   46.3*   63.2†   47.6*   6.3   60.7†   0.4 
  PEFR,  L/min  (9.6) (8.9) (9.3) (8.8) (9.2) (9.9) (9.2) (9.4)
*p < 0.05; †p ≤ 0.001; ‡change from study baseline. 
Abbreviations: FVC, forced vital capacity; ITT, intent-to-treat; PBO, placebo; PEFR, peak expiratory ﬂ  ow rate; SEM, standard error of mean; SMI, Soft MistTM Inhaler. 
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Discussion
The aim of this dose-ranging study was to identify the doses 
of tiotropium delivered from the Respimat® SMI that were 
effective and well tolerated, and were most comparable with 
tiotropium 18 μg HandiHaler®. All active doses used with 
Respimat® SMI improved the primary endpoint (trough FEV1 
after 3 weeks of treatment), and reduced rescue medication 
use compared with placebo. In general, tiotropium 5 and 
10 μg Respimat® SMI were most comparable to tiotropium 
18 μg HandiHaler® in terms of some efﬁ  cacy measures and 
pharmacokinetics. The tiotropium 20 μg dose did not offer 
additional efﬁ  cacy advantages over those observed with 5 and 
10 μg, and the systemic exposure was much higher compared 
with tiotropium 18 μg HandiHaler®. As a result, this higher 
dose (20 μg) was not investigated further in phase III studies 
of tiotropium using Respimat® SMI.
Previous studies (Newman et al 1996, 1998), which 
compared ﬂ  unisolide delivery from Respimat® SMI with a 
metered dose inhaler (MDI), showed that signiﬁ  cantly more 
ﬂ  unisolide was delivered to the lungs with the Respimat® 
SMI device. In one study the lung deposition was almost 
twice that observed with an MDI (45% versus 26%, respec-
tively) (Newman et al 1998). Similar ﬁ  ndings have been 
observed when Respimat® SMI was compared with a dry 
powder inhaler (DPI); the lung deposition of budesonide was 
46%–57% with Respimat® SMI compared with 14%–33% 
from a Turbuhaler DPI used with fast and slow peak inhaled 
ﬂ  ow rates (Pitcairn et al 2005).
These ﬁ  ndings therefore show that the Respimat® SMI 
device offers increased lung deposition and lower oropharyn-
geal deposition, compared with other devices; this beneﬁ  t may 
be irrespective of the drug used. This selective delivery pattern 
could therefore improve the therapeutic ratio of inhaled medica-
tions when delivered via Respimat® SMI. It will also enable a 
lower nominal dose of drug to be used with Respimat® SMI. 
In one study, a 50% reduction in dose of ipratropium/fenoterol 
was appropriate with Respimat® SMI to achieve similar 
therapeutic efﬁ  cacy to an MDI (Kilfeather et al 2004).
In the present study, all active treatments were well toler-
ated. Dry mouth was more common on active treatment than 
placebo, which was not surprising given the anticholinergic 
effect of tiotropium; this has also been shown in previous 
studies (Vincken et al 2002; Brusasco et al 2003; Koumis and 
Samuel 2005). The incidence of dry mouth was lower in all 
tiotropium doses below 10 μg; for example, 5 μg Respimat® 
SMI group compared with tiotropium 10 μg and tiotropium 
18 μg HandiHaler® (4% versus 11.5% and 8%, respectively), 
which is suggestive of dose dependency. Based on the prin-
ciples of seamless transition from phase II to phase III studies, 
it is prudent to carry forward one or two “best” doses (Bretz 
et al 2006). Phase III trials have further examined tiotropium 
5 and 10 μg doses for use with Respimat® SMI. Dry mouth is 
unlikely to be an issue with the lower tiotropium dose without 
compromising efﬁ  cacy in these clinical studies.
In conclusion, based on the safety, efﬁ  cacy, and pharma-
cokinetics data obtained in this study, the 5 and 10 μg doses of 
tiotropium administered with Respimat® SMI can reasonably 
be considered as the best choice of safe and effective doses 
and are, in general, the most comparable doses with the active 
comparator, tiotropium 18 μg HandiHaler®.
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Table 4  Total and individual adverse events (AEs) reported in  5% of patients in any treatment group
 Respimat® SMI  HandiHaler®
Dose, μg 1.25  2.5  5  10  20 PBO  18 Placebo
All  treated  patients  25 28 25 26 26 24 25 23
Total,* n(%)  6   9   7   8   6   5   9   6 
  (24.0) (32.1) (28.0) (30.8) (23.1) (20.8) (36.0) (26.1)
COPD   0  4   2   2   3  3   5   1 
exacerbation    (14.3) (8.0)  (7.7)  (11.5) (12.5) (20.0) (4.3)
Dry mouth  1   0  1   3   2   0  2   0
 (4.0)    (4.0)  (11.5)  (7.7)    (8.0) 
*Overall number of AEs per treatment group.
Abbrevations: COPD, chronic obstructive pulmonary disease; PBO, placebo; SMI, Soft MistTM Inhaler.International Journal of COPD 2007:2(4) 565
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